.png)
Assistant Professor
New York University
New York, New York, United States
Ryan McCormack, MD, MS, is an Assistant Professor at New York University School of Medicine, NIH-funded clinical investigator, and practicing emergency medicine clinician with background in Emergency, Internal, and Addiction Medicine. Recently, he completed a K23 training through the National Institute on Alcohol Abuse and Alcoholism (NIAAA) through which he studied the feasibility and impact of treating ED patients with severe alcohol use disorder and extreme use of the ED using extended-release naltrexone. He is Lead investigator of two linked National Institute On Drug Abuse (NIDA) Clinical Trials Network (CTN) multicenter mixed-methods implementation-effectiveness studies evaluating the feasibility, acceptability, sustainability, and impact of ED-initiated buprenorphine and referral programs in rural and urban settings with high need, limited resources, and different staffing structures, and he is Co-I of the NIDA-CTN 0099 30-site hybrid implementation-effectiveness trial comparing sublingual and extended-release buprenorphine. He is PI of a NIDA R61/R33 to further develop and test opioid use disorder treatment quality measures through a multicenter hybrid implementation-effectiveness trial that compares the relative effectiveness of the ED and ED-observation approaches to buprenorphine treatment initiation. He is Co-I if He is director of a New York State funded ED-based substance use screening and intervention program inclusive of overdose education and naloxone distribution, and has collaborated with and/or is supported by local and Federal governmental organizations, Emergency Medicine Foundation, ACEP and other academic institutions on myriad initiatives to promote education, and to develop and support the dissemination of best practices related to substance use disorder prevention and treatment.